Shanghai Shyndec Pharmaceutical News

Announcement Regarding Holding Subsidiary Pharmaceutical Passed Generic Drug Consistency Evaluation

Aug 11 12:00 ET

Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.

Jul 30 12:00 ET

Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs

Jul 30 12:00 ET

Announcement regarding the resignation of senior management personnel.

Jul 24 12:00 ET

Announcement regarding the subsidiary obtaining the pharmaceutical supplementary application approval letter.

Jul 18 12:00 ET

Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs

Jul 15 12:00 ET

Announcement on Obtaining Approval Notice for Supplementary Application of Pharmaceutical

Jul 15 12:00 ET

Announcement on the Progress of the Pharmaceutical Marketing Authorization Transfer Contract.

Jul 11 12:00 ET

Announcement regarding the holding subsidiary's acquisition of pharmaceutical registration certificate.

Jul 8 12:00 ET

Announcement regarding obtaining overseas marketing authorization for injectable cefuroxime sodium.

Jun 20 12:00 ET

Announcement regarding the holding subsidiary's acquisition of pharmaceutical registration certificate.

Jun 13 12:00 ET

Voluntary Information Disclosure Announcement Regarding Pharmaceutical Subsidiary's Consistent Evaluation of Generic Drugs

Jun 13 12:00 ET

Announcement on the full subsidiary's receipt of approval for active pharmaceutical ingredient marketing application

Jun 13 12:00 ET

Announcement regarding the active pharmaceutical ingredient of the wholly-owned subsidiary obtaining CEP certificate.

Jun 7 12:00 ET

Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders

May 28 12:00 ET

2023 Annual General Meeting of Shareholders Legal Opinions

May 28 12:00 ET

Notice on termination of the cooperation framework agreement at the end of the term

May 22 12:00 ET

Progress announcement on the signing of the “Drug Marketing License Transfer Contract” by the holding subsidiary

May 22 12:00 ET

Notice on wholly-owned subsidiaries obtaining drug registration certificates

May 14 12:00 ET

2023 Annual General Meeting of Shareholders Meeting Materials

May 13 12:00 ET